Uterine Cancer: Screening, Diagnosis, and Treatment (Current Clinical Oncology)

There are an estimated 41,000 new cases of Uterine and Endometrial Cancer each year in the United States alone, resulting in roughly 7300 deaths. In __Uterine Cancer: Screening, Diagnosis and Treatment__, Franco Muggia, Esther Oliva and a panel of prominent medical and gynecologic oncologists survey all aspects of Uterine and Endometrial Cancer, including current screening methods, staging and prognostic factors, and available treatment options. The discussion includes the role of imaging in the diagnosis and treatment of endometrial cancer, the molecular pathology and genetics of uterine cancer and the essential epidemiology of cancer of the endometrium. Authoritative and highly practical, __Uterine Cancer: Screening, Diagnosis and Treatment__ is the definitive text on the most common cancer of the female genital tract, and a must-have for all gynecological residents and fellows, as well as gynecological oncologists and family practice doctors who wish to provide their patients with the best possible care. For the Editors, the task of writing a Preface is most satisfying. It represents the completion of the book and a moment of reflection on whether the whole is more than the sum of all the parts. And also, one must reflect on how this book is likely to be utilized in this era of rapid communications. The Editors first met in May 2003 at a stimulating Italian symposium on endometrial cancer (organizers Drs. Luigi Frigerio, Roberto Grassi and Andrea Lissoni, with participation of the deans of Italian Gynecologic Oncology, Ugo Bianchi and Constantino Mangioni) that took place at Bergamo and Caravaggio. The impressive gains in biology and clinical trials were further discussed by the two editors and others that are co-authors in this venture on this side of the Atlantic at a 2004 Educational Session at the American Society of Clinical Oncology (ASCO). The pace of progress in various aspects of management of uterine cancer was no- worthy, not only was tumor biology fueling novel hypotheses such as questioning the mesenchymal origin of carcinosarcomas, but knowledge of molecular pathways was beginning to be applied as prognostic and as predictive factors portending benefit from systemic therapies. Surgical staging and sensitive imaging provided the underpinning for refining our treatment algorithms. Finally, a role for che- therapy had finally become established, principally through phase III studies c- paring chemotherapy to radiation in mostly locally advanced stages III and IV that had undergone resection. Front Matter....Pages i-xi The Essential Epidemiology of Cancer of the Endometrium....Pages 1-12 Endometrial Cancer....Pages 13-24 Imaging in the Diagnosis and Treatment of Endometrial Cancer....Pages 25-50 Uterine Cancer....Pages 51-86 Molecular Pathology and Cytogenetics of Endometrial Carcinoma, Carcinosarcoma, and Uterine Sarcomas....Pages 87-104 Prognostic Factors in Uterine Cancer....Pages 105-141 Primary Hormonal Therapy of Endometrial Cancer....Pages 143-160 Early-Stage Endometrial Cancer....Pages 161-173 Early-Stage Endometrial Cancer....Pages 175-192 Therapeutic Modalities in Early-Stage Uterine Papillary Serous Carcinomas, Carcinosarcomas, Clear-Cell and Mixed Histology Carcinomas....Pages 193-216 Treatment of Advanced and Recurrent Carcinoma....Pages 217-222 Treatment of Advanced and Recurrent Carcinoma: Chemotherapy....Pages 223-235 Treatment for Advanced and Recurrent Carcinoma: Combined Modalities....Pages 237-249 Management of Uterine Sarcomas....Pages 251-265 Future Directions: New Targets....Pages 267-283 Back Matter....Pages 285-296